Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) Enterprise Value (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Enterprise Value for 11 consecutive years, with -$4.5 billion as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 73.08% to -$4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.5 billion through Dec 2025, down 73.08% year-over-year, with the annual reading at -$4.5 billion for FY2025, 73.08% down from the prior year.
  • Enterprise Value for Q4 2025 was -$4.5 billion at BeOne Medicines, down from -$4.0 billion in the prior quarter.
  • The five-year high for Enterprise Value was -$1.9 billion in Q1 2022, with the low at -$5.7 billion in Q2 2022.
  • Average Enterprise Value over 5 years is -$3.5 billion, with a median of -$3.2 billion recorded in 2023.
  • The sharpest move saw Enterprise Value crashed 243.11% in 2021, then surged 60.56% in 2022.
  • Over 5 years, Enterprise Value stood at -$2.2 billion in 2021, then plummeted by 102.24% to -$4.5 billion in 2022, then grew by 30.0% to -$3.2 billion in 2023, then rose by 17.23% to -$2.6 billion in 2024, then plummeted by 73.08% to -$4.5 billion in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$4.5 billion, -$4.0 billion, and -$2.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.